Marvel Presenting at the 2025 Bloom Burton & Co. Conference

Company Overview - Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that employs a "drug redevelopment" approach to drug development [4] - The company focuses on creating new, patent-protected derivatives of off-patent drugs, optimizing them for additional indications, which significantly reduces time, cost, and risk compared to traditional biotech models [4] - Marvel's lead compound targets the A2a adenosine receptor, with potential applications in neurological diseases such as Alzheimer's Disease, as well as cognitive and behavioral health conditions like Depression and Anxiety [4] - The company is also exploring its lead compound's potential in treating neurodevelopmental disorders, including Autism, Rett Syndrome, and Fragile X Syndrome [4] Industry Engagement - Marvel Biosciences Corp. will attend and present at the Bloom Burton & Co. Healthcare Investor Conference on May 5 and 6, 2025, at the Metro Toronto Convention Centre [1][2] - The conference aims to connect U.S., Canadian, and international investors with the latest developments in the Canadian healthcare sector [2] - Marvel's CEO Rod Matheson and CSO Mark Williams will participate in a group presentation and one-on-one meetings with investors at the conference [2][3]